Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 5/20 | 0.46 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 2/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28410455 | 0.96 | CA4 (0.54) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL28272622 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL6321642 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL28108693 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL1401729 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL29145675 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL5610258 | 0.91 | SLC34A1 (0.54) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL7083907 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL15270770 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 | |
| Phosphoric Acid SCHEMBL28145512 | 0.91 | LMNA (0.47) | LMNACA4FAHD1CA1SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749824-A | Crosslinked polystyrene spheroid preparation dispersant and preparation method thereof | 丹东明珠特种树脂有限公司 | 2017-05-31 | — | — | CN | claimed |
| US-5631140-A | JOINING GLUCOSE TO HEMOGLOBIN, TREATMENT WITH PROTEOLYTIC ENZYME TO FORM PEPTIDE MIXTURE, SEPARATION AND MEASUREMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1997-05-20 | — | — | US | claimed |
| US-3956118-A | PRECIPITATION WITH RARE EARTH SALT, CIRCULATION | ROCKWELL INTERNATIONAL CORPORATION (US) | 1976-05-11 | — | — | US | claimed |
| US-20240100311-A1 | METHODS AND DEVICES TO PREVENT PREMATURE BIRTH | NINE MEDICAL, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11819648-B2 | Methods and devices to prevent premature birth | NINE MEDICAL, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023137523-A1 | RECOVERING RARE EARTH ELEMENTS | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-07-27 | — | — | WO | disclosed |
| US-20200360674-A1 | METHODS AND DEVICES TO PREVENT PREMATURE BIRTH | NINE MEDICAL, INC. | 2020-11-19 | — | — | US | disclosed |
| EP-3169373-B1 | BIOLOGICAL TISSUE ADHESIVE COMPOSITION AND METHOD OF PREPARATION THEREOF | UNIV NANYANG TECH (SG) | 2020-11-18 | — | — | EP | disclosed |
| US-10773062-B2 | Methods and devices to prevent premature birth | NINE MEDICAL, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| EP-2971010-B1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNATX INC (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190142971-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | MODERNA THERAPEUTICS, INC. | 2019-05-16 | — | — | US | disclosed |
| CN-1124937-C | Ink Jetting recording method | CANON KK (JP) | 2003-10-22 | — | — | CN | disclosed |
| US-20010051813-A1 | Systems, methods, and compositions for achieving closure of vascular puncture sites | NEOMEND, INC. | 2001-12-13 | — | — | US | disclosed |
| CN-1069370-C | High gloss printing paper for ink jet recording, method for producing the same, and ink jet recording method using the same | CANON KK (JP) | 2001-08-08 | — | — | CN | disclosed |
| CN-1305894-A | Ink jetting recording method | CANON KK (JP) | 2001-08-01 | — | — | CN | disclosed |
| CN-1262704-A | Unique multifunctional product for detergent formulations | VITRO CORP (MX) | 2000-08-09 | — | — | CN | disclosed |
| WO-1999002643-A1 | UNIQUE MULTIFUNCTIONAL PRODUCT FOR DETERGENT FORMULATIONS | VITRO CORPORATIVO, S.A. DE C.V. (MX) | 1999-01-21 | — | — | WO | disclosed |
| CN-1122395-A | High gloss printing paper for ink jet recording, method for producing the same, and ink jet recording method using the same | CANON KK (JP) | 1996-05-15 | — | — | CN | disclosed |
| US-4276127-A | Channel plate electron multipliers | U.S. PHILIPS CORPORATION (US) | 1981-06-30 | — | — | US | disclosed |
| EP-0006651-A1 | Channel plate electron multipliers | PHILIPS ELECTRONICS UK LIMITED (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142971-A1 | FORMULATION AND DELIVERY OF MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, ADAR | LMNA 94/4885CA4 4358/4885FAHD1 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.